Efficacy and safety of cefpodoxime in the treatment of acute otitis media in children

El‐Shabrawi, Mortada; Tolba, Omar Atef; El-Adly, Tarek Z.

doi:10.1016/j.epag.2016.03.001

Cited by 4 publications

(3 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Majority of the current survey respondents reported that cefpodoxime was the most preferred oral drug for the treatment of acute otitis media. According to El-Shabrawi et al, cefpodoxime was an effective, safe, and welltolerated antimicrobial agent for the treatment of acute otitis media in children, making it an excellent choice for empirical treatment [22]. Similarly, Fulton and Perry concluded that cefpodoxime was a safe and effective treatment for pediatric patients with acute otitis media, demonstrating good bacteriological and clinical efficacy [23].…”

Section: Discussionmentioning

confidence: 99%

Expert Opinion on the Prescription Practice of Cefpodoxime in the Management of Respiratory Tract Infections in Indian Settings

2024

J. Adv. Med. Med. Res.

View full text Add to dashboard Cite

Background: Cefpodoxime's prodrug form was absorbed and de-esterified by enterocytes to release the active metabolite, and it shows good In vitro activity against bacterial pathogens causing common RTIs. It was unknown, nevertheless, how clinicians considered about cefpodoxime. Objective: To gather expert opinion on the use of cefpodoxime in the management of respiratory tract infections (RTIs) in Indian settings. Methodology: The cross-sectional survey utilized a 19-item, multiple-response questionnaire to gather expert opinions from specialists with expertise in managing RTIs. The survey encompassed questions about current prescription practices, clinical observations, preferences, and experiences related to the use of cefpodoxime in routine settings for RTI management. The data were analyzed using descriptive statistics. Results: Approximately 53% of the clinicians reported prescribing cefpodoxime in cases of upper respiratory tract infections (URTIs), while 44% of them indicated using it for lower respiratory tract infections (LRTIs). Cefpodoxime emerged as the most commonly prescribed antimicrobial agent for treating URTIs, as reported by 86% of the clinicians. Majority (86.02%) of the clinicians favored cefpodoxime as the oral drug of choice for treating acute otitis media. More than half (68.34%) of the clinicians indicated prescribing cefpodoxime for approximately 5 to 7 days in cases of URTIs. The advantages of cefpodoxime, including its broad spectrum, favorable pharmacokinetic profile, and good bacteriological and clinical efficacy, were acknowledged by 65% of clinicians. Conclusion: The survey findings corroborated cefpodoxime as a widely used antibiotic in Indian settings for managing URTIs and acute otitis media. Clinicians reported that its broad-spectrum coverage, favorable pharmacokinetic profile, and clinical efficacy contribute to its popularity in the management of RTIs.

show abstract

Section: Discussionmentioning

confidence: 99%

Expert Opinion on the Prescription Practice of Cefpodoxime in the Management of Respiratory Tract Infections in Indian Settings

2024

J. Adv. Med. Med. Res.

View full text Add to dashboard Cite

show abstract

“…Its relatively long t 1/2 time of excretion (1.9-2.8 h) allowed for less frequent dosing (Table 3) [88,121,132]. Cefpodoxime is effective in curing urinal and respiratory infections, including some skin conditions [133]. It is poorly soluble in water (400 µg/mL) and the recent computational studies showed that it is even less soluble in many other solvents.…”

Section: Cefpodoximementioning

confidence: 99%

FDA-Approved Oximes and Their Significance in Medicinal Chemistry

2022

View full text Add to dashboard Cite

Despite the scientific advancements, organophosphate (OP) poisoning continues to be a major threat to humans, accounting for nearly one million poisoning cases every year leading to at least 20,000 deaths worldwide. Oximes represent the most important class in medicinal chemistry, renowned for their widespread applications as OP antidotes, drugs and intermediates for the synthesis of several pharmacological derivatives. Common oxime based reactivators or nerve antidotes include pralidoxime, obidoxime, HI-6, trimedoxime and methoxime, among which pralidoxime is the only FDA-approved drug. Cephalosporins are β-lactam based antibiotics and serve as widely acclaimed tools in fighting bacterial infections. Oxime based cephalosporins have emerged as an important class of drugs with improved efficacy and a broad spectrum of anti-microbial activity against Gram-positive and Gram-negative pathogens. Among the several oxime based derivatives, cefuroxime, ceftizoxime, cefpodoxime and cefmenoxime are the FDA approved oxime-based antibiotics. Given the pharmacological significance of oximes, in the present paper, we put together all the FDA-approved oximes and discuss their mechanism of action, pharmacokinetics and synthesis.

show abstract

“…12 Cefpodoxime's excellent PK/PD profile is further substantiated by the fact that it reaches adequate concentrations in the middle-ear fluid of paediatric patients based on recommended dosing frequencies. 11,13 Cefpodoxime is also stable to hydrolysis by commonly encountered plasmid-mediated β-lactamases making it particularly useful in the treatment of upper airways infections where β-lactamases producing organisms are often the source of infection. 2 Cefpodoxime is ideally suited to research effectiveness of an antimicrobial in empiric treatment (the norm) of respiratory tract infections in the community setting.…”

Section: Introductionmentioning

confidence: 99%

Brand innovator versus multisource cefpodoxime in respiratory tract infections: A comparative study

Snyman

Medlen

2019

S Afr Fam Pract

View full text Add to dashboard Cite

Purpose: In everyday practice clinicians are overwhelmed by claims from the pharmaceutical industry and, due to marketing efforts, they often view generic multisource products with scepticism despite proof and registration by regulatory authorities of bioequivalence. The primary aim of this study was exploratory and aimed to compare the acceptability of generic cefpodoxime (Cepodem®) versus the innovator brand product (Orelox®) in terms of effectiveness, safety and tolerability in a general private practice setting in South Africa in the treatment of upper and lower respiratory tract infections.Methods and patients: Ninety patients were recruited and randomised to receive either product for 10 days after clinical diagnoses of either tonsillo-pharyngitis or rhino-sinusitis or pneumonia.Results: It was demonstrated that both products resulted in similar clinical and bacteriological cure rates with also no difference in tolerability profiles.Conclusion: These findings support the bioequivalence data as submitted for regulatory approval, of the generic Cepodem® translating into clinical effectiveness and argues against the need for a clinical non-inferiority study to demonstrate sameness.

show abstract

Efficacy and safety of cefpodoxime in the treatment of acute otitis media in children

Cited by 4 publications

References 20 publications

Expert Opinion on the Prescription Practice of Cefpodoxime in the Management of Respiratory Tract Infections in Indian Settings

Expert Opinion on the Prescription Practice of Cefpodoxime in the Management of Respiratory Tract Infections in Indian Settings

FDA-Approved Oximes and Their Significance in Medicinal Chemistry

Brand innovator versus multisource cefpodoxime in respiratory tract infections: A comparative study

Contact Info

Product

Resources

About